TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06365632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus
Description: An antegrade appendectomy is performed, after which 50 to 100 ml of Antispike is applied in a thin layer to the surface of the cecum, the surface of adjacent organs and the parietal peritoneum of the right iliac region. The wound is sutured tightly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antegrade appendectomy
Description: An antegrade appendectomy is performed without using Antispike.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: antegrade appendectomy
Description: An antegrade appendectomy is performed without using Antispike.
Study: NCT05153096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBL-015
Description: NBL-015 by intravenous infusion
Study: NCT05469659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Description: Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
Study: NCT04670978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxe combined with bevacizumab biosimilar
Description: albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
Study: NCT05767177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucemia following Mixed Meal Test
Description: On day 12 of each diet, a venous catheter is placed in one arm for blood sampling and the research person must answer questions about any gastrointestinal complaints in connection with the current diet. At approximately 09:00, the research subject may eat a brunch for approximately 15 minutes (sandwich, juice, fried egg and sausage; 550-600kcal). Venous blood samples are taken before and 15, 30, 45, 60, 90 and 120 minutes after the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteroscopy - mucosal ketogenic activity as well as glucose transport
Description: On day 14 of each diet period, an enteroscopy is performed. This step is performed to obtain samples (biopsy) of the mucosa of the small intestine (duodenum and jejunum) and is performed at the Gastro-endoscopic departments SU-Sahlgrenska, or SU-Eastern hospital. Endoscopy is experienced by some individuals as unpleasant, which is why local anesthesia and sometimes sedation (midazolam + pethidine or rapifen) can be offered according to standard routine in the endoscopy department.
Study: NCT06266728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total30 for Astigmatism Contact Lenses
Description: Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
Study: NCT05437120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study: NCT06363721

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PerioPull™
Description: PerioPull™ is a natural oil rinse formula to support overall oral/gum health, tooth stains, and natural teeth whitening. PerioPull™ includes Medium Chain Triglycerides (C8, C10, C12) (from coconut oil), Bixa orellana (Annatto) Seed Extract (GG-Gold®), Natural Mint Flavor, Bromelain, Ubiquinone, Delta Tocotrienols.
Study: NCT05073107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Dental Application, Dental Monitoring (DM)
Description: o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos.
Study: NCT01996475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets
Study: NCT05075811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ossium vBM-MSC
Description: Vertebral bone marrow derived mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT05580133

Intervention type: PROCEDURE
Intervention: anterior cruciate ligament reconstruction
Description: Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.

Intervention type: PROCEDURE
Intervention: anterior cruciate ligament reconstruction
Description: Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
Study: NCT05462847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer acetate
Description: 8ml/kg Ringer acetate over 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: 8ml/kg Ringer acetate over 10 minutes
Study: NCT05106309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg CVL-231 as IR formulation
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 as slow-release MR formulation
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 as medium release MR formulation
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 as fast release MR formulation
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 Target Release, Fasted
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 Target Release, Fed
Description: Capsules
Study: NCT01411254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） High Dose

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT04851587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person (or Remote) Intervention
Description: Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
Study: NCT04649255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Embolic
Description: Lava Liquid Embolic System (LES)
Study: NCT06080828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Posterior Tibial Nerve Stimulation
Description: 20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Percutaneous Posterior Tibial Nerve Stimulation
Description: placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home instructions
Description: they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home instructions
Description: they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
Study: NCT04706676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Description: Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group: home-based training program
Description: The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational counseling session
Description: Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational counseling session
Description: Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms.
Study: NCT06183723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of social-behavior model and eHealth
Description: The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q\&A services.~The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.~The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects.
Study: NCT05294055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 1.5-1.8g/m2, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 1.5-1.8g/m2, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50mg/kg or 2g/m2, for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50mg/kg or 2g/m2, for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim, day 2
Description: Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim, day 2
Description: Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim, day 5
Description: Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim, day 5
Description: Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
Study: NCT05183607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Nutrition Education
Description: 4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
Study: NCT05453058

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
Description: Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice.
Study: NCT04301154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVIS DNA/MVA-CMDR
Description: HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVIS DNA + Cervarix and MVA-CMDR
Description: Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Cervarix by IM needle injection at weeks 0, 4 and 24.
Study: NCT04964427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
Study: NCT05895942

Intervention type: DRUG
Intervention: Imatinib
Description: The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
Study: NCT04858477

Intervention type: OTHER
Group type: OTHER
Intervention: Visual estimation of polyp size
Description: For each colonoscopy, a fellow will first visually estimate the polyp size

Intervention type: OTHER
Group type: OTHER
Intervention: Napoleon measurement of polyp size
Description: For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
Study: NCT05311124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra Dermal Regeneration template (IDRT)
Description: Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
Study: NCT05722119

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray GI
Description: Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray GI
Description: Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
Study: NCT06423573

Intervention type: DRUG
Intervention: Filsuvez
Description: Topical gel
Study: NCT05071950

Intervention type: OTHER
Group type: OTHER
Intervention: Control period
Description: * first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: D-allulose period
Description: * \[started after 7 days of control period\],~* participants continued with D-allulose period for 7 days continuously~* participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal~* a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose
Study: NCT05227638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
Study: NCT05627284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stoma reversal with bio-mesh placement
Description: Patients will receive stoma reversal. During the surgery, a bio-mesh is placed beyond the peritoneum on the surgical site to strengthen the abdominal wall.